Related Experiment Video
Updated: Jun 14, 2025
09:01
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
3.1K
Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy
Julia Nowak-Jary1, Artur Płóciennik2, Beata Machnicka1
1Department of Biotechnology, Institute of Biological Sciences, University of Zielona Gora, 65-516 Zielona Gora, Poland.
International Journal of Molecular Sciences
|August 29, 2024
Summary
Magnetic nanoparticles functionalized with APTES or CMC efficiently carried methotrexate (MTX) to target ovarian cancer cells. This approach reduced toxicity and showed comparable efficacy to free MTX, with potential for enhanced therapy via hyperthermia.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Ovarian cancer remains a significant health challenge, necessitating novel therapeutic strategies.
- Drug delivery systems, particularly nanoparticles, offer potential for targeted cancer therapy.
- Methotrexate (MTX) is a chemotherapeutic agent with limitations in efficacy and toxicity.
Purpose of the Study:
- To develop and characterize magnetic iron oxide nanoparticles (MNPs) as nanocarriers for methotrexate (MTX).
- To evaluate the efficacy and toxicity of MTX-loaded MNPs against ovarian cancer cell lines.
- To explore the potential of combining magnetic targeting and hyperthermia for enhanced cancer treatment.
Main Methods:
- Synthesis and functionalization of MNPs with (3-aminopropylo)trietoksysilan (APTES) or N-carboxymethylchitosan (CMC).
- Characterization using FT-IR, TEM, DLS, zeta potential, and magnetization measurements.
- MTX conjugation via ionic or amide bonds, followed by drug release studies and cytotoxicity assays (MTT) in 2D and 3D ovarian cancer models.
Main Results:
- Successful functionalization and characterization of APTES- and CMC-modified MNPs.
- MTX-loaded MNPs demonstrated no inherent toxicity and exhibited comparable cytotoxicity to free MTX against ovarian cancer cells.
- Magnetic targeting potential was confirmed, suggesting localized drug delivery and reduced systemic toxicity.
Conclusions:
- Functionalized magnetic nanoparticles serve as effective nanocarriers for methotrexate delivery to ovarian cancer cells.
- The developed nanocarrier system shows promise for targeted cancer therapy, potentially reducing side effects.
- Further investigation, including advanced 3D models and hyperthermia integration, is warranted to optimize therapeutic outcomes.
